Photodiagnosis and Photodynamic Therapy
Volume 7, Issue 1 , Pages 24-32 , March 2010

Taking treatment decisions in non-melanoma skin cancer—The place for topical photodynamic therapy (PDT)

  • A. Sidoroff, MD

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +43 512 504 22971; fax: +43 512 504 22990.
    • ,
  • P. Thaler

References 

  1. Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis—an update. Br J Dermatol. 2007;157(Suppl. 2):18–20
  2. Lober BA, Lober CW, Accola J. Actinic keratosis is squamous cell carcinoma. J Am Acad Dermatol. 2000;43(5 Pt 1):881–882
  3. Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol. 2006;16(6):599–606
  4. Ackerman AB. Solar keratosis is squamous cell carcinoma. Arch Dermatol. 2003;139(9):1216–1217
  5. Yantsos VA, Conrad N, Zabawski E, et al. Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Semin Cutan Med Surg. 1999;18(1):3–14
  6. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma (“actinic keratosis”). J Am Acad Dermatol. 2000;42(1 Pt 2):11–17
  7. Fu W, Cockerell CJ. The actinic (solar) keratosis: a 21st-century perspective. Arch Dermatol. 2003;139(1):66–70
  8. Rowert-Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156(Suppl. 3):8–12
  9. Anwar J, Wrone DA, Kimyai-Asadi A, et al. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004;22(3):189–196
  10. Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol. 1998;139(6):1033–1039
  11. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994;131(4):455–464
  12. Lira MG, Mazzola S, Tessari G, et al. Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br J Dermatol. 2007;157(1):49–57
  13. Salmon-Ehr V, Grosieux C, Potron G, et al. Multiple actinic keratosis and skin tumors secondary to hydroxyurea treatment. Dermatology. 1998;196(2):274
  14. Braakhuis BJ, Tabor MB, Kummer JA, et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63(8):1727–1730
  15. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42(1 Pt 2):23–24
  16. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1(8589):795–797
  17. Callen JP, Bickers DR, Moy RL. Actinic keratoses. J Am Acad Dermatol. 1997;36(4):650–653
  18. Mullen JT, Feng L, Xing Y, et al. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol. 2006;13(7):902–909
  19. Perrem K, Lynch A, Al Nooh F, et al. The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population. Hum Pathol. 2008;39(7):1034–1041
  20. Kossard S, Rosen R. Cutaneous Bowen's disease. An analysis of 1001 cases according to age, sex, and site. J Am Acad Dermatol. 1992;27(3):406–410
  21. Leibovitch I, Huilgol SC, Selva D, et al. Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52(6):997–1002
  22. Reizner GT, Chuang TY, Elpern DJ, et al. Bowen's disease (squamous cell carcinoma in situ) in Kauai, Hawaii. A population-based incidence report. J Am Acad Dermatol. 1994;31(4):596–600
  23. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen's disease. British Association of Dermatologists. Br J Dermatol. 1999;141(4):633–641
  24. Management of Bowen's disease of the skin. Drug Ther Bull 2004;42(2):13–6.
  25. Foote JA, Harris RB, Giuliano AR, et al. Predictors for cutaneous basal-and squamous-cell carcinoma among actinically damaged adults. Int J Cancer. 2001;95(1):7–11
  26. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen's disease: 2006 update. Br J Dermatol. 2007;156(1):11–21
  27. Jaeger AB, Gramkow A, Hjalgrim H, et al. Bowen disease and risk of subsequent malignant neoplasms: a population-based cohort study of 1147 patients. Arch Dermatol. 1999;135(7):790–793
  28. Jacobs DM, Sandles LG, Leboit PE. Sebaceous carcinoma arising from Bowen's disease of the vulva. Arch Dermatol. 1986;122(10):1191–1193
  29. Kao GF. Carcinoma arising in Bowen's disease. Arch Dermatol. 1986;122(10):1124–1126
  30. Lear JT, Smith AG. Basal cell carcinoma. Postgrad Med J. 1997;73(863):538–542
  31. Owens DM, Watt FM. Contribution of stem cells and differentiated cells to epidermal tumours. Nat Rev Cancer. 2003;3(6):444–451
  32. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, et al. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2007;157(Suppl. 2):47–51
  33. Cunneen TS, Yong JL, Benger R. Lung metastases in a case of metatypical basal cell carcinoma of the eyelid: an illustrative case and literature review to heighten vigilance of its metastatic potential. Clin Experiment Ophthalmol. 2008;36(5):475–477
  34. Buljan M, Bulat V, Situm M, et al. Variations in clinical presentation of basal cell carcinoma. Acta Clin Croat. 2008;47(1):25–30
  35. Lear W, Dahlke E, Murray CA. Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. J Cutan Med Surg. 2007;11(1):19–30
  36. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol. 2002;147(1):41–47
  37. Swanbeck G, Hillstrom L. Analysis of etiological factors of squamous cell skin cancer of different locations. 4. Concluding remarks. Acta Derm Venereol. 1971;51(2):151–156
  38. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ. 2003;327(7418):794–798
  39. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000;136(12):1524–1530
  40. Ramachandran S, Fryer AA, Strange RC. Genetic factors determining cutaneous basal cell carcinoma phenotype. Med Pediatr Oncol. 2001;36(5):559–563
  41. Ramachandran S, Fryer AA, Smith AG, et al. Basal cell carcinoma. Cancer. 2000;89(5):1012–1018
  42. Schmieder GJ, Yoshikawa T, Mata SM, et al. Cumulative sunlight exposure and the risk of developing skin cancer in Florida. J Dermatol Surg Oncol. 1992;18(6):517–522
  43. Clairmont A, Sies H, Ramachandran S, et al. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis. 1999;20(7):1235–1240
  44. Lear JT, Heagerty AH, Smith A, et al. Multiple cutaneous basal cell carcinomas: glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual. Carcinogenesis. 1996;17(9):1891–1896
  45. Ramachandran S, Hoban PR, Ichii-Jones F, et al. Glutathione S-transferase GSTP1 and cyclin D1 genotypes: association with numbers of basal cell carcinomas in a patient subgroup at high-risk of multiple tumours. Pharmacogenetics. 2000;10(6):545–556
  46. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984;10(6):1043–1060
  47. Ting PT, Kasper R, Arlette JP. Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg. 2005;9(1):10–15
  48. Karthiga KS, Sivapatha Sundharam B, Manikandan R. Nevoid basal cell carcinoma syndrome. Indian J Dent Res. 2006;17(1):50–53
  49. Ahmed N, Salman M, Mansoor MA. Gorlin-Goltz syndrome. J Coll Physicians Surg Pak. 2007;17(9):568–569
  50. Evans DG, Ladusans EJ, Rimmer S, et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30(6):460–464
  51. Ortega Garcia de Amezaga A, Garcia Arregui O, Zepeda Nuno S, et al. Gorlin-Goltz syndrome: clinicopathologic aspects. Med Oral Patol Oral Cir Bucal. 2008;13(6):E338–E343
  52. Maroto MR, Porras JL, Saez RS, et al. The role of the orthodontist in the diagnosis of Gorlin's syndrome. Am J Orthod Dentofacial Orthop. 1999;115(1):89–98
  53. Hansen JP, Drake AL, Walling HW. Bowen's Disease: a four-year retrospective review of epidemiology and treatment at a university center. Dermatol Surg. 2008;34(7):878–883
  54. McIntyre WJ, Downs MR, Bedwell SA. Treatment options for actinic keratoses. Am Fam Physician. 2007;76(5):667–671
  55. Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995;131(2):176–181
  56. Breuninger H, Sebastian G, Kortmann RD, et al. Brief guidelines: basal cell carcinoma of the skin. J Dtsch Dermatol Ges. 2006;4(5):441–443
  57. Jeffes EW. Levulan: the first approved topical photosensitizer for the treatment of actinic keratosis. J Dermatolog Treat. 2002;13(Suppl. 1):S19–S23
  58. Jeffes EW, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol. 2001;45(1):96–104
  59. Jeffes EW, Tang EH. Actinic keratosis. Current treatment options. Am J Clin Dermatol. 2000;1(3):167–179
  60. Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004;140(1):41–46
  61. Klein A, Babilas P, Karrer S, et al. Photodynamic therapy in dermatology—an Update 2008. J Dtsch Dermatol Ges. 2008;
  62. Morton C, Campbell S, Gupta G, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol. 2006;155(5):1029–1036
  63. Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol. 2006;142(6):729–735
  64. Morton CA. Methyl aminolevulinate (Metvix) photodynamic therapy—practical pearls. J Dermatolog Treat. 2003;14(Suppl. 3):23–26
  65. Morton CA. Methyl aminolevulinate: actinic keratoses and Bowen's disease. Dermatol Clin. 2007;25(1):81–87
  66. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007;56(1):125–143
  67. Patel GK, Goodwin R, Chawla M, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2006;54(6):1025–1032
  68. Baptista J, Martinez C, Leite L, et al. Our PDT experience in the treatment of non-melanoma skin cancer over the last 7 years. J Eur Acad Dermatol Venereol. 2006;20(6):693–697
  69. Fader DJ, Lowe L. Concomitant use of a high-energy pulsed CO2 laser and a long-pulsed (810nm) diode laser for squamous cell carcinoma in situ. Dermatol Surg. 2002;28(1):97–99[discussion 100]
  70. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol. 2002;47(2):258–262
  71. de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156(2):222–230
  72. Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol Surg. 2000;26(8):728–732
  73. Freeman RG, Knox JM, Heaton CL. The treatment of skin cancer. A statistical study of 1,341 skin tumors comparing results obtained with irradiation, surgery, and curettage followed by electrodesiccation. Cancer. 1964;17:535–538
  74. Zide MF. Actinic keratosis: from the skin to the lip. J Oral Maxillofac Surg. 2008;66(6):1162–1176
  75. Spira M, Freeman R, Arfai P, et al. Clinical comparison of chemical peeling dermabrasion, and 5-fu for senile keratoses. Plast Reconstr Surg. 1970;46(1):61–66
  76. Winton GB, Salasche SJ. Dermabrasion of the scalp as a treatment for actinic damage. J Am Acad Dermatol. 1986;14(4):661–668
  77. Trimas SJ, Ellis DA, Metz RD. The carbon dioxide laser. An alternative for the treatment of actinically damaged skin. Dermatol Surg. 1997;23(10):885–889
  78. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146(1):94–100
  79. Witheiler DD, Lawrence N, Cox SE, et al. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg. 1997;23(3):191–196
  80. Misiewicz J, Sendagorta E, Golebiowska A, et al. Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, comparative study. J Am Acad Dermatol. 1991;24(3):448–451
  81. Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1991;24(5 Pt 1):738–743
  82. Burgess GH, Bloch A, Stoll H, et al. Effect of topical tubercidin on basal cell carcinomas and actinic keratoses. Cancer. 1974;34(2):250–253
  83. Edwards L, Levine N, Smiles KA. The effect of topical interferon alpha 2b on actinic keratoses. J Dermatol Surg Oncol. 1990;16(5):446–449
  84. Edwards L, Levine N, Weidner M, et al. Effect of intralesional alpha 2-interferon on actinic keratoses. Arch Dermatol. 1986;122(7):779–782
  85. Cham BE, Daunter B, Evans RA. Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides. Cancer Lett. 1991;59(3):183–192
  86. Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial, Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev. 1997;6(11):949–956
  87. Alberts D, Ranger-Moore J, Einspahr J, et al. Safety and efficacy of dose-intensive oral vitamin A in subjects with sun-damaged skin. Clin Cancer Res. 2004;10(6):1875–1880
  88. Stritt A, Merk HF, Braathen LR, et al. Photodynamic therapy in the treatment of actinic keratosis. Photochem Photobiol. 2008;84(2):388–398
  89. Morton CA, Brown SB, Collins S, et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol. 2002;146(4):552–567
  90. Naylor MF, Boyd A, Smith DW, et al. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol. 1995;131(2):170–175
  91. Moriarty M, Dunn J, Darragh A, et al. Etretinate in treatment of actinic keratosis. A double-blind crossover study. Lancet. 1982;1(8268):364–365
  92. Morton CA, Whitehurst C, Moseley H, et al. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol. 1996;135(5):766–771
  93. Ahmed I, Berth-Jones J, Charles-Holmes S, et al. Comparison of cryotherapy with curettage in the treatment of Bowen's disease: a prospective study. Br J Dermatol. 2000;143(4):759–766
  94. Blank AA, Schnyder UW. Soft-X-ray therapy in Bowen's disease and erythroplasia of Queyrat. Dermatologica. 1985;171(2):89–94
  95. Dupree MT, Kiteley RA, Weismantle K, et al. Radiation therapy for Bowen's disease: lessons for lesions of the lower extremity. J Am Acad Dermatol. 2001;45(3):401–404
  96. Tantikun N. Treatment of Bowen's disease of the digit with carbon dioxide laser. J Am Acad Dermatol. 2000;43(6):1080–1083
  97. Ormerod AD. Recommendations in British Association of Dermatologists guidelines. Br J Dermatol. 2005;153(3):477–478
  98. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005;153(3):486–497

PII: S1572-1000(09)00167-7

doi: 10.1016/j.pdpdt.2009.12.004

Photodiagnosis and Photodynamic Therapy
Volume 7, Issue 1 , Pages 24-32 , March 2010

Article Tools